Posted by Michael Wonder on 12 Dec 2023
Orchard Therapeutics receives Swissmedic approval for Libmeldy in early-onset MLD
11 December 2023 - Orchard Therapeutics today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy (atidarsagene autotemcel), a haematopoietic stem cell gene therapy, for the treatment of early-onset metachromatic leukodystrophy.
Libmeldy was previously approved by the European Commission and UK Medicines and Healthcare products Regulatory Agency.
